Francisco Marty
Infectious Disease · Boston, MANPI 1710940283
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.1%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. Merck accounts for 76.5% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2019 at $25,975 and has fallen 87.2% since, to $3,326 in 2021. Among infectious disease clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 23 payments — averaging $1593.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$28K
- Regeneron$3K
- Gilead$3K
- Janssen Global Services, LLC$2K
Across 300 payments — averaging $20,662 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$4.3M
- Regeneron$730K
- Merck$672K
- Takeda Pharmaceuticals U.S.A., Inc.$260K
- Shire North American Group Inc$224K
- Pfizer$7K
- plus $60 from 1 others
What the payments were for
- Consulting fees$8,96524%
- Speaking & faculty fees$18,38150%
- Travel & lodging$9,15125%
- Food & beverage$1640%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 10 | $28,028 |
| Regeneron | 10 | $3,293 |
| Gilead | 2 | $3,180 |
| Janssen Global Services, LLC | 1 | $2,160 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Veklury$1,070
How this compares
$36,661 in reported general payments places this provider in the 95th percentile of 368 infectious disease providers in Massachusetts.
Other infectious disease in Boston
- Yoav GolanBoston$1.1M
- Nesli BasgozBoston$901K
- Todd EllerinBoston$843K
- Paul SaxBoston$320K
- Davidson HamerBoston$221K
- Camille KottonBoston$195K
- David SnydmanBoston$141K
- Eric RosenbergBoston$134K
- Deborah HungBoston$130K
- Laura KogelmanBoston$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.